# Ipamorelin Dosage in the Research: Doses Studied, Routes, and Half-Life > Ipamorelin dosage as studied: rat bone doses (18-450 microg/day SC), the human IV range, ~2 h half-life, routes, and the CJC-1295 stack question. Research context only, no human dosing. The doses, routes, and half-life reported in the literature, in third person, with the figures attached to their sources. ## Read this first This page reports the ipamorelin dosage figures that appear in published studies. It is not a dosing guide and contains no instruction for any person to take anything. Ipamorelin is not an approved drug, so there is no labeled human dose to cite — only what researchers gave to animals and, in two small studies, to volunteers. In rats, bone studies used microgram-per-day amounts split through the day; in humans, the only doses were given by IV drip in a lab. The compound clears from human blood with a half-life of roughly 2 hours, and the growth-hormone burst it triggers peaks about 40 minutes after a dose. Community "stack" routines that pair it with CJC-1295 by subcutaneous injection have no controlled human dosing evidence behind them, and this page treats them as exactly that — unverified. ## Doses studied in animals Rodent skeletal work used subcutaneous microgram-range doses divided across the day. The defining bone-growth study gave 18, 90 and 450 microg/day SC, split three times daily for 15 days, and saw a stepwise rise in longitudinal bone growth rate [2]. A bone-mineral study delivered 0.5 mg/kg/day continuously by osmotic minipump for 12 weeks [3]. A steroid-rescue study used 100 microg/kg SC three times daily for 3 months [4], and a related study delivered 0.4-1.6 mg/kg/day IV in four divided doses to probe the growth-hormone response under glucocorticoid load [5]. Other models pushed higher and used different routes. Rat postoperative-ileus work used 0.1-1 mg/kg IV repeated four times daily, and the 2024 ferret cachexia study used 1-3 mg/kg intraperitoneal [8]. Across these, the route, frequency, and dose were chosen for the experimental question — they are not a template for anything outside the lab. ## Doses studied in humans Human dosing exists in just two published settings, both intravenous and lab-administered. The pharmacology study infused single doses of `4.21`, `14.02`, `42.13`, `84.27`, and `140.45 nmol/kg` over 15 minutes in healthy men to map the kinetics [6]. The Phase 2 ileus trial gave 0.03 mg/kg IV twice daily for up to 7 days in 114 bowel-resection patients [7]. There is no published human subcutaneous dosing study, despite subcutaneous injection being the dominant route in off-label use — a gap stated plainly on the [Ipamorelin effects](/effects) page. ## Half-life and pharmacokinetics In healthy human volunteers ipamorelin showed a terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg, with dose-proportional (linear) kinetics across the studied range [6]. The pharmacodynamic readout was a single discrete growth-hormone pulse peaking at about 0.67 h — roughly 40 minutes — after dosing [6]. In rats, plasma clearance is reported to be roughly five-fold lower than that of GHRP-6. The short half-life and single-pulse profile are why community protocols emphasize timing rather than continuous exposure, though no human study validates any such schedule. ## Routes studied Five routes appear in the literature, each tied to a purpose. Intravenous dosing carries the human PK and clinical-trial data and much of the rodent efficacy work [6] [7]. Subcutaneous dosing dominates the rodent bone and body-composition studies and is the most common route in community use [2] [3]. Intranasal delivery has been characterized in rodents at roughly 20% bioavailability. Intraperitoneal dosing appears in rodent and ferret efficacy studies [8]. Oral dosing applies only to engineered ipamorelin-derived analogs (about 10% bioavailability in dog); ipamorelin itself is not orally bioavailable. ## How to reconstitute cjc-1295 ipamorelin 5mg Reconstitution questions come up constantly for the CJC-1295/ipamorelin combination, and the honest answer is a handling note, not a protocol. Research peptides like ipamorelin ship as a lyophilized (freeze-dried) powder — free base or acetate salt — and are reconstituted with bacteriostatic water for laboratory handling; as peptides they degrade with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated [6]. These are general peptide-handling observations from the research-supply literature, not a clinical preparation instruction, and no specific volume or concentration is endorsed here because there is no approved human formulation to anchor one to. ## How much cjc-1295 ipamorelin should i take There is no evidence-based answer to how much CJC-1295/ipamorelin a person should take, because no controlled human trial has tested the combination for any outcome [16]. Community "stack" protocols pair the two by subcutaneous injection, but those regimens have no peer-reviewed human dosing basis and are anecdotal, not recommended [7]. The only human ipamorelin doses ever published were intravenous and lab-administered [6] [7]. This site reports those study figures in third person and does not convert them into a personal dose. ## Is cjc-1295 ipamorelin safe Whether CJC-1295/ipamorelin is safe cannot be answered from controlled human data, because none exists for the combination. The single ipamorelin Phase 2 trial showed no ipamorelin-specific safety signal over a 7-day IV window [7], but a 28-day study of a related GHS-R1a agonist found dose-dependent heart-muscle damage in rats [9], and long-term cardiovascular safety of chronic ipamorelin dosing in humans is uncharacterized. The cited safety cautions — cancer, glucose, cardiovascular, appetite — are detailed on the [Ipamorelin effects](/effects) page. ## Is ipamorelin fda approved Ipamorelin is not FDA approved for any indication. It was investigated for postoperative ileus (`NCT00672074`) but the trial missed its primary endpoint [7], and no Phase 3 followed. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting, tightening compounding-pharmacy access. It is marketed only as a research chemical, and it is prohibited in sport at all times under WADA category S2. --- A data-forward read of the ipamorelin record — the rat bone-growth numbers and the cortisol-sparing GH pulse logged first, each figure pinned to the study that measured it and the thin, mostly-negative human evidence left plainly thin; a reading console, not a clinic, a vendor, or a prescription.